Fig. 1. Treatment with CAR(NAP) T cells targeting endogenous tumour-associated antigens delays tumour growth and prolongs survival in immunocompetent mouse cancer models.
a, Retroviral constructs used for mouse T-cell engineering. b,c, Treatment schedules for CAR-engineered T cells of subcutaneous murine A20 lymphoma that endogenously express murine CD19 (b), and murine NXS2 neuroblastoma that endogenously express GD2 (c). d, e, A20 tumour size (mean) until the first mouse had to be killed (d) and mouse survival (Kaplan–Meier curve) after treatment (e); arrows in e indicate rechallenge of cured mice with A20 tumour cells. f, g, NXS2 tumour size (mean) until the first mouse had to be killed (f) and mouse survival (Kaplan–Meier curve) after treatment (g). The A20 experiment was performed once, and the NXS2 experiment was performed twice and all data points were pooled. Tumour sizes between treatment groups were compared using two-way ANOVA, and survival curves were compared using the log-rank test. Error bars represent s.e.m. (NS, no statistical significance; *P < 0.05, ***P < 0.001, ****P < 0.0001). Precise P values are reported in Supplementary Table 3.